By designing proteins de novo scientists can more efficiently create novel therapeutics tailored for specific biological ...

Advances are occurring in spectroscopy, reducing the challenges of rapid signal saturation and the need for extensive sample prep.

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.

In addition to being faster and less invasive than a traditional tissue biopsy, the blood test is also potentially more accurate.

PRDX6 and GSTP1 identified as promising enzyme targets for neuroblastoma, offering an alternative to retinoic acid differentiation therapy.

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

Chrysalis partners with life science clients, from early-stage biofirms to pharmaceutical firms, CROs, and other life science ...

PepGen leverages a graph-based approach to improve the detection of hidden protein variants in a computationally efficient ...

While commercial uptake by patients still lags and a recent court decision rekindles a legal battle, clinical successes ...

Nanoneedle tech could enable disease monitoring in real time, allowing clinicians to take multiple, repeatable tests from the ...

GEN ranks not only the top 10 publicly traded developed of editing-based therapies, but the top five privately held companies ...